RxDoctor Payments Data

Callisia Clarke, MD

Surgical Oncology · Milwaukee, WINPI 1275752578

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $12,740 of the $15,610 with a category attached, or 81.6%. Ipsen Biopharmaceuticals, Inc accounts for 94.7% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $14,898, more than ten times the $110 reported in 2019. Among surgical oncology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,610in general payments, 2019–2025

Across 20 payments — averaging $780.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Biopharmaceuticals, Inc$15K
  • AstraZeneca$132
  • Johnson & Johnson$131
  • Medtronic$121
  • Boston Scientific$119
  • Regeneron Healthcare Solutions, Inc.$110
  • plus $216 from 3 others

What the payments were for

  • Speaking & faculty fees$12,74082%
  • Travel & lodging$1,3339%
  • Food & beverage$1,53810%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,610 in reported general payments places this provider in the 95th percentile of 40 surgical oncology providers in Wisconsin.

See all surgical oncology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$40,160
Medicare patients
71
Services billed
191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other surgical oncology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →